Related Experiment Videos
Discordance between phenotype and genotype in malignant hyperthermia
1Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.
Current Opinion in Neurology
|October 1, 1995
Summary
Malignant hyperthermia susceptibility is primarily linked to ryanodine receptor gene mutations. However, some families lack this link, suggesting other genetic factors and diagnostic test limitations for malignant hyperthermia.
Area of Science:
- Genetics
- Molecular Biology
- Anesthesiology
Background:
- Malignant hyperthermia (MH) is a severe pharmacogenetic disorder of skeletal muscle.
- Genetic linkage studies have identified mutations in the ryanodine receptor gene (RYR1) on chromosome 19q13.1 as a primary cause of MH.
- However, a significant portion of MH families remain unlinked to RYR1, indicating genetic heterogeneity.
Purpose of the Study:
- To review the genetic basis of malignant hyperthermia.
- To discuss the challenges in linkage studies for MH.
- To highlight the limitations of the caffeine halothane contractures test in diagnosing MH.
Main Methods:
- Review of existing literature on malignant hyperthermia genetics.
- Analysis of linkage data for MH families.
- Evaluation of diagnostic methods for malignant hyperthermia.
Main Results:
- Eight mutations in the ryanodine receptor gene (RYR1) are associated with malignant hyperthermia.
- Alternative loci on chromosomes 7q21-22 and 3q13.1 have been linked to a small number of MH families.
- The caffeine halothane contractures test may be inadequate for accurate phenotypic diagnosis in some MH cases.
Conclusions:
- While RYR1 mutations are the most common cause of malignant hyperthermia, other genetic factors likely contribute.
- Further research is needed to identify additional MH susceptibility genes.
- Improved diagnostic methods are crucial for accurate identification of individuals with malignant hyperthermia.